United States Newborn Screening Market Size, Share, In-Depth Analysis, Opportunity and Forecast 2025-2033

Kommentarer · 9 Visningar

United States newborn screening market size reached USD 109.3 Million in ​2024​. Looking forward, IMARC Group expects the market to reach USD 211.0 Million by ​2033​, exhibiting a growth rate (CAGR) of 7.58% during 2025-2033.

IMARC Group has recently released a new research study titled “United States Newborn Screening Market Report by Product (Instruments, Reagents), Technology (Tandem Mass Spectrometry, Pulse Oximetry, Enzyme Based Assay, DNA Assay, Electrophoresis, and Others), Test Type (Dry Blood Spot Test, CCHD, Hearing Screen), and Region 2025-2033”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.

United States Newborn Screening Market Overview

The United States newborn screening market size reached USD 109.3 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 211.0 Million by 2033, exhibiting a growth rate (CAGR) of 7.58% during 2025-2033.

Market Size and Growth

Base Year: 2024

Forecast Years: 2025-2033

Historical Years: 2019-2024

Market Size in 2024: USD 109.3 Million

Market Forecast in 2033: USD 211.0 Million

Market Growth Rate (2025-2033): 7.58 %

Request for a sample copy of the report: https://www.imarcgroup.com/united-states-newborn-screening-market/requestsample

 Key Market Highlights:

✔️ Market growth supported by rising awareness of early disease detection in infants
✔️ Growing adoption of advanced genetic & metabolic screening technologies
✔️ Supportive government policies and newborn health programs boosting demand

United States Newborn Screening Market Trends and Drivers:

The United States newborn screening market is vital for the early detection of congenital disorders and metabolic diseases in infants. With advancements in technology and an increasing awareness of the significance of early diagnosis, the landscape of newborn screening is evolving rapidly. Programs are expanding to cover a broader range of conditions, which is essential for improving health outcomes. As healthcare providers and policymakers prioritize early intervention, the market is set for significant transformation.

Market Size and Growth Projections

The size of the United States newborn screening market is projected to experience substantial growth in the coming years. By 2025, the market is expected to expand significantly due to several factors, including the rising incidence of genetic disorders and advancements in screening technologies. The integration of next-generation sequencing (NGS) and other innovative diagnostic methods is enhancing the accuracy and efficiency of newborn screening programs. Consequently, healthcare systems are increasingly investing in these technologies to ensure comprehensive screening for newborns, further driving market expansion.

Market Share Dynamics

The United States newborn screening market is characterized by a diverse array of participants, including public health programs, private laboratories, and biotechnology companies. Traditional screening methods, such as blood tests for metabolic disorders, continue to dominate the market. However, by 2025, there is a notable shift towards more advanced technologies, including genetic testing and digital health solutions. This transition is expected to redistribute market share among existing players while also creating opportunities for new entrants focused on innovative screening solutions, thereby reshaping the competitive landscape.

Future Trends and Considerations

As the growth of the United States newborn screening market accelerates, several trends will shape its future. Increased collaboration among healthcare providers, policymakers, and technology developers is essential for establishing standardized screening protocols and improving access to testing. Additionally, public awareness campaigns that emphasize the importance of newborn screening will drive demand for comprehensive programs. By 2025, a focus on personalized medicine and tailored interventions is expected to further enhance the effectiveness of newborn screening initiatives, ultimately leading to improved health outcomes for infants across the nation.

United States Newborn Screening Market Segmentation:

The market report segments the market based on product type, distribution channel, and region:

Product Insights:

  • Instruments
  • Reagents

Technology Insights:

  • Tandem Mass Spectrometry
  • Pulse Oximetry
  • Enzyme Based Assay
  • DNA Assay
  • Electrophoresis
  • Others

Test Type Insights:

  • Dry Blood Spot Test
  • CCHD
  • Hearing Screen

Regional Insights:

  • Northeast
  • Midwest
  • South
  • West

Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=21054&flag=C

Competitive Landscape:

The market research report offers an in-depth analysis of the competitive landscape, covering market structure, key player positioning, top winning strategies, a competitive dashboard, and a company evaluation quadrant. Additionally, detailed profiles of all major companies are included.

Key Highlights of the Report

1. Market Performance (2019-2024)
2. Market Outlook (2025-2033)
3. COVID-19 Impact on the Market
4. Porter’s Five Forces Analysis
5. Strategic Recommendations
6. Historical, Current and Future Market Trends
7. Market Drivers and Success Factors
8. SWOT Analysis
9. Structure of the Market
10. Value Chain Analysis
11. Comprehensive Mapping of the Competitive Landscape

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302

Kommentarer